- Home
- PTLO vs XNCR Comparison
PTLO vs XNCR Comparison
Compare PTLO & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTLO
- XNCR
- Stock Information
- Founded
- PTLO 1963
- XNCR 1997
- Country
- PTLO United States
- XNCR United States
- Employees
- PTLO N/A
- XNCR N/A
- Industry
- PTLO Restaurants
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- PTLO Consumer Discretionary
- XNCR Health Care
- Exchange
- PTLO Nasdaq
- XNCR Nasdaq
- Market Cap
- PTLO 548.6M
- XNCR 547.8M
- IPO Year
- PTLO 2021
- XNCR 2013
- Fundamental
- Price
- PTLO $7.08
- XNCR $8.13
- Analyst Decision
- PTLO Buy
- XNCR Buy
- Analyst Count
- PTLO 8
- XNCR 9
- Target Price
- PTLO $13.00
- XNCR $25.00
- AVG Volume (30 Days)
- PTLO 4.2M
- XNCR 710.1K
- Earning Date
- PTLO 08-05-2025
- XNCR 08-06-2025
- Dividend Yield
- PTLO N/A
- XNCR N/A
- EPS Growth
- PTLO 17.90
- XNCR N/A
- EPS
- PTLO 0.46
- XNCR N/A
- Revenue
- PTLO $727,754,000.00
- XNCR $146,929,000.00
- Revenue This Year
- PTLO $7.95
- XNCR $22.06
- Revenue Next Year
- PTLO $12.38
- XNCR N/A
- P/E Ratio
- PTLO $15.53
- XNCR N/A
- Revenue Growth
- PTLO 3.62
- XNCR N/A
- 52 Week Low
- PTLO $6.88
- XNCR $6.92
- 52 Week High
- PTLO $15.78
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- PTLO 29.66
- XNCR 51.82
- Support Level
- PTLO $6.88
- XNCR $7.71
- Resistance Level
- PTLO $7.19
- XNCR $8.33
- Average True Range (ATR)
- PTLO 0.26
- XNCR 0.46
- MACD
- PTLO 0.08
- XNCR 0.09
- Stochastic Oscillator
- PTLO 15.04
- XNCR 62.36
About PTLO Portillo's Inc.
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. It owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, Barnelli's pasta, sides and soup, and desserts and shakes.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.